查看购物车
  • Traditional Chinese
  • Japanese
  • Korean
分子即时诊断（mPOC）市场：市场展望与创新（2024-2029）
市场调查报告书
商品编码
1669754

分子即时诊断（mPOC）市场：市场展望与创新（2024-2029）

Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029
出版日期: | 出版商: Kalorama Information | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

分子即时诊断（mPOC）彻底改变体外诊断（IVD）领域，提供分子检测的灵敏度和特异性以及传统即时诊断（POC）解决方案的可及性和速度。

mPOC 从一种新兴技术创新转变为一种主要的市场力量，其驱动力是急诊室、门诊诊所、医生办公室和社区护理环境对快速准确的诊断解决方案的需求不断成长。 COVID-19 疫情加速了技术的应用，特别是在呼吸道检测领域，但市场仍在继续扩展到新的领域，例如医院内感染（HAI）、性传染感染（STI）和热带疾病。

本报告调查分子即时诊断（mPOC）市场，对快速发展的市场的全面分析，涵盖了至2029年五年的预测市场规模、成长前景、竞争格局等。

目录

第1章 执行摘要

第2章 分子即时诊断市场的发展与趋势

  • COVID-19 和分子 POC
  • 监理发展
  • 联盟、资金和奖项
  • 业务
  • 分子即时诊断的优点和缺点
  • 理由：敏感度/特异性论点
  • 新系统和选单扩展
  • 交易与投资 mPOC 系统
  • 中国作为 POC 市场
  • POC 诊断中的常见测试和分析物
  • 分子即时诊断的基本技术
    • 微流体
    • 定量 PCR
    • 微阵列
    • 等温扩增
    • 测试自动化
    • 引子和探针
    • 侦测
    • 新一代定序
    • 分子诊断
    • 即时 PCR（qPCR）
    • 等温扩增法
    • 环介导等温扩增（LAMP）
    • 切口酶扩增反应（NEAR）
    • 链置换扩增（SDA）
    • 解旋酶依赖性扩增（HDA）
    • 基于核酸序列的扩增（NASBA）
    • 转录介导扩增（TMA）
    • 交叉启动扩增（CPA）
    • 线探针分析
  • 分子即时诊断应用与潜在应用
    • 分子 POC 诊断的主要测试
    • 流感
    • RIDT 的重新分类
    • 医院内感染（HAI）
    • 链球菌A
    • 呼吸道合胞病毒（RSV）
    • 新用途
    • 兹卡病毒
    • 其他呼吸道感染
    • B 型链球菌
    • 人类乳突病毒
    • 单纯疱疹病毒
    • 阴道炎
    • 肺结核
    • 疟疾
    • 其他热带疾病和被忽视的疾病
    • 癌症
  • 欧洲设备法规

第3章 市场分析

  • 分子即时诊断市场分析
  • 区域市场占有率
  • 依疾病领域细分
  • 床边分子检测市场
  • 床边分子检测供应商市场占有率

第4章 公司简介

  • Abbott Laboratories
  • Aidian Oy
  • Akonni Biosystems
  • binx health, inc.
  • Biocartis NV
  • bioMerieux SA
  • Cepheid (Danaher)
  • Credo Diagnostics Biomedical Pte. Ltd.
  • Curetis NV (OpGen)
  • DiaSorin S.p.A
  • GenMark Diagnostics (Roche)
  • Greiner Bio-One GmbH
  • Lucira Health (Pfizer)
  • Meridian Bioscience, Inc. (SD Biosensor)
  • Mesa Biotech, Inc. (Thermo)
  • QIAGEN NV
  • QuantuMDx Group
  • QuidelOrtho Corporation
  • Roche
  • Sekisui Diagnostics LLC
  • T2 Biosystems
简介目录
Product Code: 25-018KA

Molecular point-of-care (mPOC) diagnostics are revolutionizing the in vitro diagnostics (IVD) landscape, delivering the sensitivity and specificity of molecular testing with the accessibility and speed of traditional point-of-care (POC) solutions. Kalorama Information's latest report, "Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029", provides a comprehensive analysis of this rapidly evolving market, covering the size, growth trajectory, and competitive dynamics forecasted over a five year span to 2029.

Market Drivers & Opportunities

mPOC has transitioned from an emerging innovation to a major market force, driven by increasing demand for rapid and accurate diagnostic solutions in critical care units, outpatient clinics, physician offices, and community health settings. The COVID-19 pandemic accelerated adoption, particularly in the respiratory testing segment, but the market continues to expand into new areas, including hospital-acquired infections (HAIs), sexually transmitted infections (STIs), and tropical diseases.

With leading companies such as Abbott, Cepheid, bioMerieux, Roche, and QuidelOrtho competing in the space, this report explores key questions:

  • What is the size and projected growth of the mPOC market?
  • Which companies are leading the market, and how are they positioned?
  • How is mPOC impacting traditional laboratory-based molecular testing?
  • What regions and disease segments present the greatest opportunities?

Comprehensive Market Insights

This report offers detailed segmentation of the mPOC market, including:

  • Market Sizing & Forecasts (2024-2029) - Revenue projections by technology, region, and disease area.
  • Competitive Analysis - Market share breakdowns and insights into leading companies.
  • Geographic Trends - Market distribution across North America, Europe, Asia Pacific, and the Rest of the World.
  • Technology & Regulatory Landscape - Overview of CLIA-waived and moderate-complexity molecular platforms.

Scope

"Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029" provides market sizing, forecasting, trend mapping, and competitive analysis for POC tests using PCR or other molecular technology, offering fast turnaround times and usability in near-patient settings. This Kalorama Information report provides real-world analysis and modeling for relevant circumstances, with insights into near-patient molecular testing using small instruments.

This comprehensive analysis includes market shares for companies, regions, and disease types, distinguishing between "true" molecular point-of-care and near-patient molecular systems. The report highlights the competitive landscape, with major IVD companies and innovative players contributing to the market's growth. The report defines molecular point-of-care (mPOC) devices as those that run PCR or other DNA and RNA testing on a portable device, with features such as small footprint, fast result times, and usability outside of a reference lab.

A Decade of mPOC Research Expertise

Kalorama Information has been covering the mPOC market since its inception and provides real-world analysis rooted in extensive primary and secondary research. Whether you are an IVD company, investor, or healthcare provider "Molecular Point-of-Care (mPOC) Market Outlook and Innovations, 2024-2029", offers critical insights to help you navigate and capitalize on this fast-growing segment.

Table of Contents

Chapter 1: Executive Summary

  • Figure 1-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
  • Figure 1-2: Near Patient Molecular Systems Market, 2024-2029 ($ million)
  • Where is Molecular Point-of-Care in 2025?
    • Table 1-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
  • Molecular Point-of-Care Market Analysis
    • Table 1-2: Molecular Point-of-Care Market Growth, 2024-2029 (%)
    • Figure 1-3: Molecular Point-of-Care Market, by Disease Indication, 2024 (%) [COVID/Respiratory, Other]
  • Market Observations
  • "Near-Patient" Molecular Systems Market
    • Table 1-3: Near Patient Molecular Systems Market, 2024-2029 ($ million)
    • Table 1-4: Near Patient Molecular Systems Market Growth, 2024-2029 (%)
    • Table 1-5: mPOC and Near-Patient Market, 2024-2029 ($ million)
    • Figure 1-4: mPOC and Near-Patient Market, 2024-2029 ($ million)
  • Current Trends
  • Molecular Point-of-Care Diagnostics Defined
  • Usage of Molecular Point-of-Care
  • Leading mPOC Platforms
    • Table 1-6: Molecular POC Diagnostic Platforms and Technologies
  • Trends
  • Scope and Methodology

Chapter 2: Molecular Point-of-Care Market Development and Trends

  • COVID-19 and Molecular POC
    • Table 2-1: Molecular POC COVID-19 Emergency Authorizations
    • CDC Initial Response, Long Term Situation
    • COVID-19's Unique Challenge
    • BARDA Directs Funding to mPOC
  • Regulatory Developments
  • Consortia, Funding, Prizes
  • Deals
    • Table 2-2: Deals in Molecular Point-of-Care, April 2019-Feb 2025
  • Advantages and Disadvantages of Molecular Point-of-Care
    • Table 2-3: Disadvantages of Molecular Point-of-Care, by Setting [Physician Office Laboratory (POL) / Other Outpatient Settings, Developing and Low-Resource Areas, and Hospital POC]
  • Justification: The Sensitivity/Specificity Argument
  • New Systems and Menu Expansion
    • New Systems Introduced in Development
    • Combination Tests Changing Market: SARS-CoV-2, Flu A, Flu B, and RSV
    • STI Continues to Be a Growth Area
  • Deals, Investment in mPOC Systems
    • Roche Acquires LumiraDx for up to $350 Million
    • Thermo Acquires Mesa Biotech
  • China as a POC Market
  • Common Tests and Analytes in POC Diagnostics
  • Component Technologies of Molecular Point-of-Care Diagnostics
    • Microfluidics
    • qPCR
    • Microarrays
    • Isothermal Amplification
    • Test Automation
    • Primers and Probes
    • Detection
    • Next-Generation Sequencing
    • Molecular Diagnostics
    • Real-Time PCR (qPCR)
    • Isothermal Amplification Methods
    • Loop-Mediated Isothermal Amplification (LAMP)
    • Nicking Enzyme Amplification Reaction (NEAR)
    • Strand Displacement Amplification (SDA)
    • Helicase Dependent Amplification (HDA)
    • Nucleic Acid Sequence-Based Amplification (NASBA)
    • Transcription-Mediated Amplification (TMA)
    • Cross Priming Amplification (CPA)
    • Line Probe Assays
  • Applications and Potential Applications for Molecular Point-of-Care
    • Major Testing Applications for Molecular POC Diagnostics
    • Influenza
    • Reclassification of RIDTs
    • Hospital-Acquired Infections (HAIs)
    • Strep A
    • Respiratory Syncytial Virus (RSV)
    • Emerging Applications
    • Zika
    • Other Respiratory Infections
    • Group B Streptococcus
    • Human Papillomavirus
    • Herpes Simplex Virus
    • Vaginitis
    • Tuberculosis
    • Malaria
    • Other Tropical and Neglected Diseases
    • Cancer
  • European Device Regulations

Chapter 3: Market Analysis

  • Molecular Point-of-Care Market Analysis
    • Table 3-1: Molecular Point-of-Care Market, 2024-2029 ($ million) (%)
    • Figure 3-1: Molecular Point-of-Care Market, 2024-2029 ($ million)
  • Regional Shares
    • Table 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
    • Figure 3-2: Geographic Breakout of the Molecular Point-of-Care Market, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
    • Figure 3-3: Global Molecular Point-of-Care Market Share, by Region, 2024 ($ million) [APAC, Europe, North America, Rest of World]
  • Breakout by Disease Area
    • Table 3-3: Segment Breakout of Molecular Point-of-Care Market, by Disease Indication, 2024 ($ million) [COVID/Respiratory, Other]
    • Figure 3-4: Segment Breakout of Molecular Point-of-Care Market, by Disease Indication, 2024 ($ million) [COVID/Respiratory, Other]
    • Figure 3-5: Breakout of Molecular Point-of-Care Market Share, by Disease Indication, 2024 (%) [COVID/Respiratory, Other]
  • "Near Patient Molecular" Market
    • Table 3-4: Near Patient Molecular Point-of-Care Market, 2024-2029 ($ million) (%)
    • Figure 3-6: Near Patient Molecular Point-of-Care Market, 2024-2029 ($ million)
  • Vendor Market Share for Near Patient Molecular Testing
    • Table 3-5: Near Patient Molecular Testing Market Share, by Vendor, 2024 (%) [Abbott, bioMerieux, Cepheid, Roche, Other]
    • Figure 3-7: Near Patient Molecular Testing Market Share, by Vendor, 2024 (%) [Abbott, bioMerieux, Cepheid, Roche, Other]

Chapter 4: Company Profiles

  • Abbott Laboratories
  • Aidian Oy
  • Akonni Biosystems
  • binx health, inc.
  • Biocartis NV
  • bioMerieux SA
    • Table 4-1: bioMerieux FilmArray Est. Systems per Quarter, Q4 '18-Q4 '24
    • Figure 4-1: FilmArray Systems Installed by Quarter, Q4 2018-Q4 2024
  • Cepheid (Danaher)
    • Molecular Healthcare-Acquired Infection (HAI) Testing
    • Molecular Sexual Health and Women's Health Testing
    • Molecular Critical Infectious Disease Testing
    • Molecular Oncology/Genetics Testing
  • Credo Diagnostics Biomedical Pte. Ltd.
  • Curetis NV (OpGen)
  • DiaSorin S.p.A
  • GenMark Diagnostics (Roche)
  • Greiner Bio-One GmbH
  • Lucira Health (Pfizer)
  • Meridian Bioscience, Inc. (SD Biosensor)
  • Mesa Biotech, Inc. (Thermo)
  • QIAGEN NV
  • QuantuMDx Group
  • QuidelOrtho Corporation
  • Roche
  • Sekisui Diagnostics LLC
  • T2 Biosystems